Edward C. Hsiao MD
Diabetes, Lipid Metabolism, Osteoporosis & Bone Metabolism Medicine
Assistant Professor in Residence, Internal Medicine, UCSF School of Medicine
Join to View Full Profile
4150 Clement St# 111NSan Francisco, CA 94121
Phone+1 415-750-2089
Dr. Hsiao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2009
Johns Hopkins UniversityResidency, Internal Medicine, 2001 - 2004- Johns Hopkins University School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2003 - 2027
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects Start of enrollment: 2014 Jul 14
Publications & Presentations
PubMed
- Single-cell analysis of human fibrous dysplasia bone reveals a fibrotic transcriptome and GNAS variants in endothelial, perivascular, and stromal cells.Kelly L Wentworth, Fernando A Fierro, Tania A Moody, Bryan Le, Zachary Michel
American Journal of Human Genetics. 2025-09-04 - Fibrous dysplasia/McCune-Albright syndrome: state-of-the-art advances, pathogenesis, and basic/translational research.Biagio Palmisano, Camryn Berry, Alison Boyce, Julia F Charles, Michael T Collins
Orphanet Journal of Rare Diseases. 2025-08-08 - 1 citationsPalovarotene (Sohonos), a synthetic retinoid for reducing new heterotopic ossification in fibrodysplasia ossificans progressiva: history, present, and future.Edward C Hsiao, Maurizio Pacifici
JBMR Plus. 2025-01-01
Press Mentions
Vitamin D Won’t Prevent Falls, Fractures in Older Adults. Here's What Will HelpDecember 19th, 2024
Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans ProgressivaDecember 12th, 2017
Organovo and UCSF Partner to Create 3D Bioprinted Tissues for Skeletal Disease ResearchJune 14th, 2016- Join now to see all
Grant Support
- Core Center for Musculoskeletal Biology and MedicineUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2029
- An Observational Study of IL1 Inhibition for Blocking ACVR1-Induced Flare Activity and Heterotopic Ossification in Fibrodysplasia Ossificans ProgressivaUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2028
- Novel Strategies for Understanding and Treating Fibrous DysplasiaUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
- Novel Strategies for Understanding and Treating Fibrous DysplasiaUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
- Novel Strategies for Understanding and Treating Fibrous DysplasiaUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
- the Gut Microbiome as a Disease Modifier of Heterotopic OssificationEMORY UNIVERSITY2022–2027
- Diabetes, Endocrinology & Metabolism Training GrantUNIVERSITY OF CALIFORNIA, SAN FRANCISCO1981–2027
- Diabetes, Endocrinology & Metabolism Training GrantUNIVERSITY OF CALIFORNIA, SAN FRANCISCO1981–2027
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
